NCT03933319: Phase II Study of Pegylated Liposomal Doxorubicin (PLD) Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

NCT03933319
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must either be 1) chemotherapy naïve in the metastatic setting or 2) had 1 prior regimen for MBC
Exclusions: Patients with symptomatic brain metastases
https://ClinicalTrials.gov/show/NCT03933319

Comments are closed.

Up ↑